Candriam Equities L Oncology Fund Class I GBP Cap

Category Sector Equity Healthcare


star-filledstar-filledstar-filledstar-filled
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price

£2,767.13

arrow-down£-22.92 (-0.82%)

Fund Code

CNOIA

BKMFNF8

LU1864482515

Prices updated as at 12 Nov 2026
|
Prices in GBP

Investment objective
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies in the field of oncology (cancer research, diagnosis, treatment, etc.) in order to respond to one of the serious long-term challenges of sustainable development. The sub-fund therefore seeks to produce a return for investors while generating a positive social impact over the long term, by selecting companies that address certain societal challenges and mobilise resources in the fight against cancer.

Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.

Fund statusOpen
Fund typeSICAV
Fund managerLinden Thomson, Servaas Michielssens, Pasquale Sansone
2790.05
2274.9
Fund comparative indexMSCI World NR USD
Healthcare and Biotechnology
-
1.01
0.24
0.00
Sector Equity Healthcare
No
Fund providerCandriam
Share class launch date25 Mar 2020
£1.30b
-
-
-
-
Please note that some funds may have small additional incidental charges that are not shown here. Where these charges do exist they are included within the variable ongoing costs in the Pre-sale Illustration.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.